

# $\beta_2$ -GLYCOPROTEIN 1

AROTEC\_Beta2GP1\_Product\_Info.pdf Version/Date: B/04.05.20

ATG01-10  $\beta_2$ -Glycoprotein 1 1.0 mg

## Description of the Product

Purified from human plasma that has been tested and found to be negative for HIV, HCV and HBsAg antibodies. After coating onto ELISA plates the product will bind autoantibodies to  $\beta_2$ -glycoprotein 1.

**Purity:** The  $\beta_2$ -glycoprotein 1 autoantigen (54 kDa) is more than 95% pure, as assessed by SDS gel electrophoresis.

**Storage:** Store at -65°C or below (long term). Avoid repeated freezing and thawing. Mix thoroughly before use.

## Clinical and Biochemical Data

Autoantibodies directed to negatively charged phospholipids, in particular cardiolipin, have been detected in the serum of patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS)<sup>1</sup>. APS is characterised by venous and arterial thrombosis, recurrent spontaneous abortions and thrombocytopenia. It is now known that a serum cofactor,  $\beta_2$ -glycoprotein 1, is required for the binding of cardiolipin by autoantibodies in the sera of patients with APS<sup>2-4</sup>. By contrast, anticardiolipin antibodies from patients with infectious diseases (in particular, syphilis) do not require this cofactor<sup>5</sup>.

$\beta_2$ -Glycoprotein 1, also known as apolipoprotein H, is a relatively abundant serum protein (present at a concentration of about 0.2 mg/ml) that may play a role in coagulation<sup>6</sup>. It has been shown to bind to platelets<sup>7</sup>, mitochondria<sup>8</sup> and negatively charged substances such as heparin<sup>9</sup>, DNA<sup>10</sup>, dextran sulphate<sup>11</sup> and negatively charged phospholipids<sup>12</sup>.  $\beta_2$ -Glycoprotein 1 is known to be very heat stable<sup>2</sup>. On SDS-electrophoresis the protein displays an apparent m.wt. of 45 kDa under non-reducing conditions and 55kDa upon reduction. Although isoelectric focussing has been reported<sup>13</sup> to reveal genetic polymorphisms of  $\beta_2$ -glycoprotein 1, the multiple bands seen by this method may be due to different amounts of sialic acid<sup>14</sup>.

The amino acid sequence of  $\beta_2$ -glycoprotein 1 reveals a 326 amino acid protein of about 36 kDa<sup>15</sup>. This sequence has been confirmed by sequencing the protein's cDNA<sup>16</sup>. The fact that the protein migrates on SDS-electrophoresis with a much larger apparent m.wt. suggests that it is extensively glycosylated.  $\beta_2$ -Glycoprotein 1 has five consensus repeats, referred to as "Sushi domains", characteristic of the complement control protein family<sup>17,18</sup>. The use of purified  $\beta_2$ -glycoprotein 1 for the detection of autoantibodies in human serum has been demonstrated by several authors<sup>19-34</sup>.

## Methodology

The following is an ELISA procedure that can be used to detect anti  $\beta_2$ -glycoprotein 1 antibodies in human serum using the ATG01 purified antigen:

1. Dilute the purified antigen to 2.0-4.0  $\mu$ g/ml in PBS (10 mM Potassium phosphate, pH 7.4, 0.15 M NaCl).
2. Coat ELISA plates with 100  $\mu$ l of diluted antigen per well. Cover and incubate overnight at +4 °C.
3. Empty the plate and remove excess liquid by tapping on a paper towel.
4. Block excess protein binding sites by adding 200  $\mu$ l PBS containing 1% BSA per well. Incubate at room temperature for 3 hours.

5. Empty plates and apply 100  $\mu$ l of serum samples diluted 1:100 in PBS / 1% BSA / 1% casein / 0.02% Tween<sup>®</sup> 20. Incubate at room temperature for 1 hour.
6. Empty plates and add 200  $\mu$ l PBS/ 0.02% Tween<sup>®</sup> 20 per well. Incubate 5 minutes then empty plates. Repeat this step twice.
7. Apply 100  $\mu$ l anti-human IgG-enzyme conjugate (horseradish peroxidase or alkaline phosphatase) diluted in PBS / 1% BSA / 1% casein / 0.02% Tween<sup>®</sup> 20 per well and incubate for 1 hour.
8. Repeat step 6.
9. Add enzyme substrate and stop the reaction when appropriate.
10. Read absorbance in an ELISA spectrophotometer.

**Note:** The type of ELISA plate<sup>28,35</sup> and the use of Tween<sup>®</sup> 20 in the wash buffer<sup>36-38</sup> are the subjects of some discussion.

## References

1. Hughes, G.R.V. (1994) *Lancet* **342**, 341
2. Galli, M. et al. (1990) *Lancet* **335**, 1544
3. Matsuura, E. et al. (1990) *Lancet* **336**, 177
4. McNeil, H.P. et al. (1991) *Proc. Natl. Acad. Sci. USA* **87**, 4120
5. Matsuura, E. et al. (1992) *J. Immunol.* **148**, 3885
6. Schousboe, I. (1985) *Blood* **66**, 1086
7. Schousboe, I. (1980) *Thromb. Res.* **19**, 225
8. Schousboe, I. (1979) *Biochim. Biophys. Acta* **579**, 396
9. Polz et al. (1980) *Int. J. Biochem.* **11**, 265
10. Kroll, J. et al. (1976) *Biochim. Biophys. Acta* **434**, 490
11. Schousboe, I. & Rasmussen, M.S. (1988) *Int. J. Biochem.* **20**, 787
12. Wurm, H. (1984) *Int. J. Biochem.* **16**, 511
13. Richter, A. & Cleve, H. (1988) *Electrophoresis* **9**, 317
14. Gries, A. et al. (1989) *Biochem. J.* **260**, 531
15. Lozier, J. et al. (1984) *Proc. Natl. Acad. Sci. USA* **81**, 3640
16. Steinkasserer, A. et al. (1991) *Biochem. J.* **277**, 387
17. Kato, H. & Enjiyoji, K. (1991) *Biochem. USA* **30**, 11687
18. Ichinose, A. et al. (1990) *J. Biol. Chem.* **265**, 13411
19. Amiral, J. et al. (1994) *Haemostasis* **24**, 191
20. Arvieux, J. et al. (1991) *J. Immunol. Methods* **143**, 223
21. Cabral, A.R. et al. (1992) *J. Autoimmunity* **5**, 787
22. El-Kadi, H.S. et al. (1995) *J. Rheumatol.* **22**, 2233
23. Erickson, E.N. et al. (1996) *Clin. Chem.* **42**, 1116
24. Gharavi, A.E. et al. (1993) *J. Lab. Clin. Med.* **122**, 426
25. Hanly, J.G. et al. (1995) *J. Rheumatol.* **22**, 1091
26. Hunt, J. & Krilis, S. (1994) *J. Immunol.* **152**, 653
27. Katano, K. et al. (1996) *Human Reprod.* **11**, 509
28. Keil, L.B. et al. (1995) *Biotechnol. Appl. Biochem.* **22**, 305
29. Martinuzzo, M.E. et al. (1995) *Brit. J. Haematol.* **89**, 397
30. Matsuura, E. et al. (1992) *J. Immunol.* **148**, 3885
31. McNally, T. et al. (1995) *Brit. J. Haematol.* **91**, 471
32. Nomura, M. et al. (1995) *Rheumatol. Int.* **15**, 1
33. Pengo, V. et al. (1995) *Thrombosis & Haemostasis* **73**, 29
34. Roubey, R.A.S. et al. (1995) *J. Immunol.* **154**, 954
35. Matsuura, E. et al. (1994) *J. Exp. Med.* **179**, 457
36. Arvieux, J. & Roussel, B. (1994) *Brit. J. Haematol.* **88**, 443
37. Matsuda, J. et al. (1993) *Brit. J. Haematol.* **85**, 799
38. Cheng, H.W. (1996) *J. Immunol. Methods* **191**, 87

**NOTE: No patented technology** has been used by AroTec during the preparation of this product.

